<DOC>
	<DOCNO>NCT00642538</DOCNO>
	<brief_summary>20 eligible subject enrol treatment phase trial .</brief_summary>
	<brief_title>A Study Designed Determine Safety Pharmacological Response ofMKC253 Inhalation Powder Adults With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>Trial objective determine safety &amp; pharmacological response MKC253 Inhalation Powder .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Nonsmoking male females 18 70 year age Body Mass Index ( BMI ) &lt; 32 kg/m2 Diabetes manage stable regimen diet exercise within precede 8 week and/or metformin and/or sulfonylurea meglitinide alpha glucosidase inhibitor , without dose adjustment within precede 8 week . For subject take metformin sulfonylurea meglitinide alpha glucosidase inhibitor , one oral agent must less 1/2 maximal allowable dose cite product label . HbA1c = 6.2 = 8.5 % . Fasting Cpeptide = 0.5 ng/mL . On last 3 day washout period ( Day 3 , 2 , 1 ) subject FBG ( finger stick ) = 13.5 mmol/L . Normal pulmonary function performance pulmonary function test Written Informed Consent Treatment type antidiabetic therapy metformin , sulfonylurea , meglitinide alpha glucosidase inhibitor within precede 12 week [ ie , thiazolidinediones ( TZDs ) , dipeptyl peptidase inhibitor ( DPPIV ) , Symlin ( pramlintide acetate ) Byetta ( exenatide ) ] . Exposure investigational medication device within previous 90 day prior trial entry participation another clinical trial participate trial . Use prescription medication within 90 day prior screen , allow antidiabetic therapy , approve PI Sponsor . The use alpha blocker , antihypertensive , proton pump inhibitor cholesterol medication comedications allow throughout study . Significant improvement pre postbronchodilator spirometry ( defined increase 12 % AND 200 mL either FVC OR FEV1 ) . Serum creatinine Upper Limit Normal ( ULN ) define laboratory Any condition , opinion PI , make subject unsuitable clinical trial , could limit validity inform consent and/or impair subject 's ability participate trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Diabetic adult male , diabetic postmenopausal woman</keyword>
</DOC>